Hypaque-Cysto

Name: Hypaque-Cysto

Commonly used brand name(s)

In the U.S.

  • Cystografin
  • Cystografin-Dilute
  • Hypaque-Cysto
  • Hypaque Meglumine
  • Reno-30
  • Reno-60
  • Reno-Dip

Available Dosage Forms:

  • Solution

Therapeutic Class: Radiological Ionic Contrast Media

Precautions While Using Hypaque-Cysto

Your doctor will check your progress closely while you are receiving this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to receive it.

Severe reactions may occur while you are receiving this medicine. Tell your doctor if you have seizures, trouble breathing, or tightness in the chest after receiving this medicine.

Before you have any medical tests, tell the medical doctor in charge that you are receiving this medicine. The results of some tests may be affected by this medicine.

Hypaque-Cysto Dosage and Administration

After the bladder is emptied, Hypaque-Cysto is gently instilled without force, often beyond the first desire to micturate, but not beyond the point of urgency or mild discomfort. The volume required to fill the bladder to slightly less than capacity may vary from patient to patient.

Bladder capacity in normal adults is generally 200 mL to 300 mL, and rarely, up to 600 mL. Capacity at birth is 20 mL to 50 mL, and increases about 400 percent in the first year. In children 3 to 5 years old, bladder capacity is 150 mL to 180 mL. In children older than 8 years, it is in the low adult range.

In disease, bladder capacity in adults may vary from 50 mL in a hypertonic reflex bladder to over 1000 mL in an atonic or sensory paralytic bladder or chronic lower urinary tract obstruction.

Repeat examination may be required to detect reflux, or in function studies.

The concentration varies with technique and equipment used. Hypaque-Cysto may be diluted with sterile water or 5 percent dextrose solution, as indicated in the following table. A 10 percent solution is isotonic.

STANDARD PACKAGE (250 mL of Hypaque-Cysto in 500 mL bottle)
TO MAKE ADD FINAL SOLUTION CONTAINS
Final conc. Final volume Sterile water or 5% dextrose solution Iodine
30% 250 mL _ 141 mg/mL
25% 300 mL 50 mL 118 mg/mL
21.4% 350 mL 100 mL 101 mg/mL
20% 375 mL 125 mL 94 mg/mL
18.8% 400 mL 150 mL 88 mg/mL
16.7% 450 mL 200 mL 78 mg/mL
15% 500 mL 250 mL 71 mg/mL

Note: To achieve the following concentrations some of the contrast agent must be removed prior to dilution.

TO MAKE REMOVE ADD FINAL SOLUTION CONTAINS
Final conc. Final volume Sterile water or 5% dextrose solution Iodine
12% 500 mL 50 mL 300 mL 56 mg/mL
12% 375 mL 100 mL 225 mL 56 mg/mL
10% 450 mL 100 mL 300 mL 47 mg/mL

Dilution and withdrawal of the contrast agent should be accomplished under aseptic conditions with sterile syringes. The solution should be inspected visually for particulate matter and discoloration prior to administration.

How is Hypaque-Cysto Supplied

STANDARD PACKAGE

Calibrated 500 mL dilution bottles containing 250 mL Hypaque-Cysto; rubber stoppered, with hangers, inner removable seal and screw neck. Box of 10 (NDC 0407-0734-10)

Protect from light. Contains no preservatives, therefore, discard any unused portion remaining in the container.

Store at 15°C to 30°C (59°F to 86°F).

Distributed by Amersham Health Inc.
Princeton, NJ 08540

Printed in USA

Revised February 2003
HNC-3D

HYPAQUE - CYSTO 
diatrizoate meglumine injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0407-0734
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
diatrizoate meglumine (diatrizoic acid) diatrizoic acid 30 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
Iodine 141 mg  in 1 mL
Packaging
# Item Code Package Description
1 NDC:0407-0734-10 10 BOTTLE (10 BOTTLE) in 1 BOX
1 500 mL (500 MILLILITER) in 1 BOTTLE
Labeler - Amersham Health Inc.
Revised: 08/2007   Amersham Health Inc.
(web3)